DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Zanosar (Streptozocin) - Summary



ZANOSAR should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents.

A patient need not be hospitalized but should have access to a facility with laboratory and supportive resources sufficient to monitor drug tolerance and to protect and maintain a patient compromised by drug toxicity. Renal toxicity is dose-related and cumulative and may be severe or fatal. Other major toxicities are nausea and vomiting which may be severe and at times treatment-limiting. In addition, liver dysfunction, diarrhea, and hematological changes have been observed in some patients. Streptozocin is mutagenic. When administered parenterally, it has been found to be tumorigenic or carcinogenic in some rodents.

The physician must judge the possible benefit to the patient against the known toxic effects of this drug in considering the advisability of therapy with ZANOSAR. The physician should be familiar with the following text before making a judgment and beginning treatment.



ZANOSAR® (streptozocin sterile powder)

Each vial of ZANOSAR contains 1 g of the active ingredient streptozocin 2-deoxy-2 [[(methylnitrosoamino)carbonyl]amino]-α (and ß)-D-glucopyranose and 220 mg citric acid anhydrous. ZANOSAR is available as a sterile, pale yellow, freeze-dried preparation for intravenous administration. The pH was adjusted with sodium hydroxide. When reconstituted as directed, the pH of the solution will be between 3.5 and 4.5.

ZANOSAR is indicated in the treatment of metastatic islet cell carcinoma of the pancreas. Responses have been obtained with both functional and nonfunctional carcinomas. Because of its inherent renal toxicity, therapy with this drug should be limited to patients with symptomatic or progressive metastatic disease.

See all Zanosar indications & dosage >>


Media Articles Related to Zanosar (Streptozocin)

New 'chemotherapy booster' could treat lung and pancreatic cancer
Source: Lung Cancer News From Medical News Today [2015.07.23]
A new drug that blocks cancer's escape route from chemotherapy could be used to treat deadly lung and pancreatic cancers, new research reports.

Blood Protein May Spot Pancreatic Cancer Early
Source: MedicineNet Pancreatic Cancer Specialty [2015.06.25]
Title: Blood Protein May Spot Pancreatic Cancer Early
Category: Health News
Created: 6/24/2015 12:00:00 AM
Last Editorial Review: 6/25/2015 12:00:00 AM

Pancreatic Cancer
Source: MedicineNet Cancer Causes Specialty [2015.05.29]
Title: Pancreatic Cancer
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 5/29/2015 12:00:00 AM

Diabetes Drug May Not Guard Against Pancreatic Cancer
Source: MedicineNet metformin Specialty [2015.04.22]
Title: Diabetes Drug May Not Guard Against Pancreatic Cancer
Category: Health News
Created: 4/21/2015 12:00:00 AM
Last Editorial Review: 4/22/2015 12:00:00 AM

Pancreatic Cancer, the Silent Disease
Source: MedicineNet Endoscopic Ultrasound Specialty [2014.12.01]
Title: Pancreatic Cancer, the Silent Disease
Category: Doctor's Views
Created: 11/1/2007 12:00:00 AM
Last Editorial Review: 12/1/2014 12:00:00 AM

more news >>

Published Studies Related to Zanosar (Streptozocin)

Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. [2005.08.01]
PURPOSE: Optimal treatments for metastatic carcinoid tumor remain undefined, and the role of chemotherapy for symptomatic patients with progressive disease is uncertain... CONCLUSION: Response to all three treatment regimens were modest. FU/STZ improved survival compared with the doxorubicin-based regimen, suggesting that the combination should be considered to be an active regimen of therapy when chemotherapy is judged to be an option for selected patients with carcinoid tumors.

Chromium, Selenium, and Zinc Multimineral Enriched Yeast Supplementation Ameliorates Diabetes Symptom in Streptozocin-Induced Mice. [2011.11.12]
Chromium, selenium, and zinc malnutrition has been implicated in the pathogenesis of diabetic mellitus. This study aims to investigate the effects of novel multiminerals-enriched yeast (MMEY) which are minerals supplementation containing elevated levels of chromium, selenium, and zinc simultaneously in a diabetic animal model...

A single institution experience of streptozocin/fluorouracil combination chemotherapy: a case series. [2011.11.03]
CONCLUSION: FU/STZ was a well-tolerated regimen that produced significant benefit in the setting of metastatic and progressive disease. Our case series demonstrated comparable progression-free survival and overall survival in relation to randomized controlled studies and previous case series.

[Effects of electroacupuncture on expression of Abeta positive cells of the hippocampus and SOD activity in rats with streptozocin-Alzheimer's disease]. [2010.12]
OBJECTIVE: To investigate the possible mechanism of the electroacupuncture for improvement of learning and memory in rats of Alzheimer's disease (AD)... CONCLUSION: Electroacupuncture treatment can reduce the Abeta protein expression and increase the SOD activity of the hippocampus so as to improve learning and memory ability in the AD rats.

Asiatic acid preserves beta cell mass and mitigates hyperglycemia in streptozocin-induced diabetic rats. [2010.09]
BACKGROUND: Type 1 diabetes is a chronic condition in which the pancreas produces little or no insulin due to the loss or dysfunction of pancreatic beta cells. This study investigated the beneficial effects of asiatic acid-a triterpenoid compound-preserved beta mass and mitigated hyperglycemia in streptozocin-induced diabetic rats... CONCLUSIONS: These results suggest that asiatic acid exerts its glucose-lowering effects, in part through influences on beta-cell mass. Asiatic acid administration resulted in preservation and restoration of beta-cell mass and function in diabetic rodent models. 2010 John Wiley & Sons, Ltd.

more studies >>

Clinical Trials Related to Zanosar (Streptozocin)

Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors [Recruiting]
RATIONALE: Drugs used in chemotherapy, such as capecitabine, streptozocin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving capecitabine together with streptozocin is more effective with or without cisplatin in treating neuroendocrine tumors.

PURPOSE: This randomized phase II trial is studying giving capecitabine together with streptozocin to see how well it works compared with or without cisplatin in treating patients with unresectable or metastatic neuroendocrine tumors.

Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors [Recruiting]
Open label, single-arm phase II study of avastin combined with fluorouracil, doxorubicin and streptozocin administered in 28-day cycles. Treatment will continue until progression of disease, or until withdrawal due to toxicity, or up to a maximum of 12 cycles (48 weeks). In order to reduce the risk of cardiac toxicity, doxorubicin will be administered for a maximum of 8 cycles. If disease has not progressed after 12 cycles of treatment, avastin monotherapy will continue until disease progression or withdrawal due to toxicity.

International Study: Comparison of Two Treatments for Adrenocortical Cancer [Recruiting]

- There is no medical consensus about the best treatment for advanced adrenocortical

cancer (ACC) that cannot successfully be treated with surgery alone.

- In 2003, the International Consensus Conference on Adrenal Cancer recommended two

chemotherapy regimens - etoposide, doxorubicin, cisplatin plus mitotane and

streptozotocin plus mitotane- as the best choices until better data could be obtained. All the drugs in the two options have been shown effective against advanced ACC, but they have different side effects.


- To determine which of the chemotherapy regimens described above is best to start with

in patients with ACC that cannot be surgically removed.

- To determine if there is a way to identify which patients will respond to a certain



- Patients 18 years of age and older from the USA, Scandinavia, Germany, Italy, France, The

Netherlands, Belgium, the UK, Canada and Australia who have adrenocortical cancer that cannot be cured with surgery alone.


- Chemotherapy: Patients are randomly assigned to start with one of the two study

regimens. Patients whose tumor continues to grow during treatment are offered the alternative therapy. All patients receive daily tablets of mitotane. In addition, they have one of the following two regimens:

- Streptozotocin every 3 weeks for up to six cycles. The first cycle is given on days 1,

2, 3, 4 and 5 and subsequent cycles are given on day 1 only.

- Cisplatin plus etoposide plus doxorubicin every 4 weeks for up to six cycles.

Doxorubicin is given on day 1, etoposide is given on days 2, 3 and 4 and cisplatin is given on days 3 and 4.

- CT scans of the chest, abdomen and pelvis approximately once every 8 weeks.

- Physical examination, routine blood tests and a check of side effects at the start of

each treatment cycle.

- Blood test to determine if the hormones produced by some adrenocortical cancers have

any effect on the immune system.

- Analysis of genetic markers in blood and tumor tissue for comparison with tumor growth

and patient survival to determine if this can help identify which patients will respond to a certain therapy.

- Optional procedures:

- Storage of blood and tissue samples for future research.

- Completion of quality-of-life questionnaires every 2 months.

Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms [Active, not recruiting]

I. Assess the clinical response of patients with refractory or recurrent brain neoplasms treated with carmustine, streptozocin, and mercaptopurine.

Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas [Completed]
Patients with Zollinger-Ellison Syndrome suffer from ulcers of the upper gastrointestinal tract, higher than normal levels of gastric acid, and tumors of the pancreas known as non-beta islet cell tumors.

Prior to the use of drugs to cure the ulcers, patients typically died due to severe ulcers. Because of such effective drugs to treat the ulcers it is more common to see patients dying due to the pancreatic tumors.

The study will observe patients suffering from Zollinger-Ellison Syndrome and non-beta islet cell tumors and determine the effectiveness of combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin.

more trials >>

Page last updated: 2015-07-23

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015